At the beginning of 2019, BMS has annouced to acquire Celgene with an equity value of $74bn. What are the most important acquisitions in the pharmaceutical industry in 2018?
1. Novartis makes offer to acquire French CDMO CellforCure
Novartis has made an offer to acquire CellforCure, a France-based contract development and manufacturing organisation (CDMO) producing cell and gene therapies in Europe, from LFB for an undisclosed amount.
2. Astellas Pharma Acquires Potenza Therapeutics
Astellas Pharma Inc. has exercised its exclusive option to acquire Potenza Therapeutics, Inc., paying $164.6 million upfront and additional payments of as much as $240.1 million, depending on the progress of various programs. The acquisition follows the successful outcome of a collaboration agreement entered in 2015 to build a portfolio of novel immuno-oncology (IO) therapies. The clinical IO therapies developed may also provide a platform for IO combinations with Astellas' existing non-IO programs for life cycle management and future novel IO combinations.
3. AMAG Pharmaceuticals Enters Into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals
Through this acquisition, AMAG will acquire global rights to ciraparantag, a next generation anticoagulant reversal agent, further enhancing its development pipeline and leveraging AMAG’s expertise in hematology.
4. GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
The transaction will significantly strengthen GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.
The agreement provides Purdue the exclusive option to acquire SpineThera, Inc. and gain worldwide rights to its products and technology platforms, including lead asset SX600, a novel dexamethasone containing microsphere that is in development for epidural administration for low back pain. This technology has potential for development of non-opioid treatments for acute and chronic pain.
6. Roche's Genentech to acquire inflammatory drug discovery firm Jecure
The proposed acquisition will give Genentech full rights to Jecure’s entire preclinical portfolio of Receptor Family Pyrin Domain Containing Protein 3 (NLRP3) inhibitors similar to nucleotide-binding oligomerisation.
7. Boehringer Ingelheim acquires MabVax’s programme for solid tumours
Boehringer Ingelheim has entered an asset acquisition and licence agreement for US-based biotechnology firm MabVax Therapeutics’ programme designed to target a glycan that is commonly overexpressed on various solid tumours cancers.
8. Sun Pharmaceutical agrees to acquire Japan’s Pola Pharma
The $1m deal will enable Sun to bolster its global dermatology business. Pola Pharma’s portfolio primarily consists of dermatology products.
9. Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion
This offer represents a premium of 54% percent to Endocyte’s closing price of $15.56 on October 17, 2018. The transaction was unanimously approved by the board of directors of Endocyte.
With the acquisition of Halo, Cambrex will enter the large and growing finished dosage form CDMO market.
11. Telix to Acquire ANMI for €5.15M
The acquisition of ANMI significantly ex...
(All Rights Reserved)